MWNA
OCUL icon

Marshall Wace North America’s Ocular Therapeutix OCUL Stock Holding History

Marshall Wace North America’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$160K Buy
+15,971
New +$179K ﹤0.01% 1339
2018
Q1 		– Sell
-25,133
Closed -$112K – 1615
2017
Q4 		$112K Buy
+25,133
New +$128K ﹤0.01% 1307

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace North America's OCUL Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Ocular Therapeutix (OCUL) in Q3 2021: 15,971 shares worth $160K. The stake represents ﹤0.01% of the portfolio and ranks #1339 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in OCUL as recently as Q4 2017.

Marshall Wace North America first reported a position in OCUL in Q4 2017 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold OCUL as of Q3 2021.

  • Marshall Wace North America held 15,971 shares of Ocular Therapeutix worth $160K as of Q3 2021.
  • Ocular Therapeutix was a new Marshall Wace North America position in Q3 2021.
  • Ocular Therapeutix made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1339 holding.
  • Marshall Wace North America first reported a position in Ocular Therapeutix in Q4 2017 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.